| Literature DB >> 31091442 |
Christina A Ortmann1, Lena Dorsheimer1, Khalil Abou-El-Ardat2, Jennifer Hoffrichter1, Birgit Assmus3, Halvard Bonig4, Anica Scholz5, Heike Pfeifer1, Hans Martin1, Tobias Schmid5, Bernhard Brüne5, Sebastian Scheich1, Björn Steffen1, Julia Riemann1, Stella Hermann6, Alexandra Dukat7, Gesine Bug1, Christian H Brandts8, Sebastian Wagner2, Hubert Serve2, Michael A Rieger9.
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutations leading to clonal blood cell expansion. However, direct evidence of the fitness of CHIP-mutated human hematopoietic stem cells (HSCs) in blood reconstitution is lacking. Because myeloablative treatment and transplantation enforce stress on HSCs, we followed 81 patients with solid tumors or lymphoid diseases undergoing autologous stem cell transplantation (ASCT) for the development of CHIP. We found a high incidence of CHIP (22%) after ASCT with a high mean variant allele frequency (VAF) of 10.7%. Most mutations were already present in the graft, albeit at lower VAFs, demonstrating a selective reconstitution advantage of mutated HSCs after ASCT. However, patients with CHIP mutations in DNA-damage response genes showed delayed neutrophil reconstitution. Thus, CHIP-mutated stem and progenitor cells largely gain on clone size upon ASCT-related blood reconstitution, leading to an increased future risk of CHIP-associated complications.Entities:
Keywords: ASCT; CHIP; autologous stem cell transplantation; chemotherapy; clonal dominance; clonal hematopoiesis; hematopoietic stem cells; hematopoietic stress; leukemia; somatic mutations
Mesh:
Year: 2019 PMID: 31091442 DOI: 10.1016/j.celrep.2019.04.064
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423